Medytox Receives Approval for 'Neuramis Volume Lidocaine' in China

[Financial News] Medytox is expanding its hyaluronic acid filler lineup in China.
Medytox announced on the 28th that it had received product approval from China's National Medical Products Administration (NMPA) for the hyaluronic acid filler 'Neuramis Volume Lidocaine.'
With the approval, Medytox has expanded the number of filler products it can sell locally to two, following the previously approved 'Neuramis Deep Lidocaine.' Both products will be sold in China under the 'Fillux' brand.
Neuramis is a hyaluronic acid filler developed using Medytox's proprietary technology. The newly approved Neuramis Volume Lidocaine contains lidocaine, a local anesthetic, and is designed to reduce pain during procedures. It is used to improve facial wrinkles and restore volume in the midface.
Medytox plans to expand its local product lineup and begin preparations for the launch as it seeks to target China's aesthetic medical market. The company is carrying out follow-up procedures with its partner and aims to launch the product in the fourth quarter.
A Medytox official said, "China's aesthetic medical market is growing rapidly, led by younger consumers. We will expand our product lineup to meet local needs and work with our partners to sustain our global growth momentum."

[email protected] Jeong Sang-hee Reporter